Pain Management

The agency warns consumers against using these products, which are marketed for topical use to relieve pain associated with cosmetic procedures.

Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

Clinical pharmacists in the ED are well positioned to facilitate adoption of ED-initiated buprenorphine and improve the treatment of patients with OUD.

Studies have shown that higher expression of CYP2D6 alleles in adults results in excessive production of active metabolites, leading to either therapeutic failure, increased exposure, or more severe adverse effects.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Tera Moore, PharmD, BCACP, discusses the principles of trauma-informed care, along with the physiologic response to trauma.

Non-expansion states had an increase in prescriptions after PA removal at 27.3% and Medicaid expansion states demonstrated a 22% decrease in prescriptions.

Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.

Bupivacaine liposome injectable suspension was shown to reduce opioid use after surgery and significantly improve pain.

Pharmacists’ pharmacotherapeutic expertise helps them advocate for their patients and assist providers.

A critical aspect of National Prescription Drug Take Back Day is the focus on Naloxone training.

Dispensing an opiate despite this request leads to the son’s death and a negligence lawsuit

Pharmacists are experts at juggling shortages of all kinds, however, and L’Altrelli said they are crucial team members regarding opioid access challenges.

Moving cannabis to Schedule 3 will make it easier to research, resulting in the development and creation of new cannabinoid-based pharmaceuticals, with notable potential in oncology.

Experts agreed that it was appropriate for patients who use methamphetamine or cocaine to continue opioid use if clinician monitoring was increased and tapering was avoided.

Despite the limited data, prior research indicates there are no serious cannabis-related adverse effects in pediatric patients.

The opioid settlement framework could have a significant impact on the future of cannabis distribution and its role in health care.

Pharmacists' expertise is invaluable to prescribers who are unfamiliar with opioid use disorder treatment protocols.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

A dose of 900 mg per day of gabapentin prior to spine surgery was associated with the lowest pain score among all studied dosages.

Study investigators suggest that there is a higher prevalence of pain and treatment needs in this small population.

A panel released recommendations in accordance with decades of a changing landscape in acetaminophen poisoning and due to an absence of agreed upon guidelines in the space.

No major changes were found in overdose behaviors among individuals who received take-home naloxone.

Author of the book The Journey’s End discusses how extending life at all costs takes away time that patients could be spending with their families during the last moments of their life.

The approval of RiVive naloxone hydrochloride nasal spray for nonprescription use provides another tool to help quickly reverse the effects of opioid overdose.

The data could inform how non–steroidal anti-inflammatory drug-mediated mitochondrial uncoupling could affect other diseases.

Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.